The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders. Specifically, the present invention relates to a method of detecting metabolic bone disorders using expression of the human DC-STAMP gene as an indicator, a pharmaceutical composition containing an antibody which is capable of specifically recognizing human DC-STAMP and suppressing formation of osteoclasts, and so forth.本發明為關於使用在破骨細胞有高表達之基因而檢定骨代謝異常之方法、有骨代謝異常治療及/或預防效果化合物之篩選法、及骨代謝異常治療及/或預防用醫藥組成物。因此，本發明為提供以人DC-STAMP基因表達為指標作為骨代謝異常之檢定方法，及含對人DC-STAMP有專一辨識、有抑制破骨細胞形成活性之抗體的醫藥組成物等。
